Privosegtor Receives Breakthrough Drug Designation - Top-Institutions - MDSpire

Privosegtor Receives Breakthrough Drug Designation

In a phase 2 trial, the drug showed functional and structural signals in optic neuritis.

  • By

  • Conexiant News Staff

  • January 6, 2026

  • 2 min

Share

Top Institutions in Ophthalmology

Brief introduction explaining scope and methodology.

  • #1

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Neuro-ophthalmology
    • Neurology
    • Ophthalmology

  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Neuro-ophthalmology
    • Neurology
    • Ophthalmology

  • #3

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Neurology
    • Ophthalmology
    • Neuro-ophthalmology

  • #4

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Neuro-ophthalmology
    • Neurology
    • Ophthalmology

Original Source(s)

Privosegtor Receives Breakthrough Drug Designation

  • by Conexiant News Staff

  • January 6, 2026

Related Content

Retinal Age Model Tied to Disease Risk

Fundus-based tool estimates biologic aging but shows modest gains over prior models

AI-driven saliency-guided retinal vessel segmentation framework for sustainable digital pathology

GLP-1 Eye Effects Raise Questions

Authors describe both potential retinal benefits and possible rare optic nerve risks, while emphasizing that long-term ocular safety data remain limited as use expands.